Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study

Psychoneuroendocrinology

Volumn 58, Issue , 2015, Pages 130-140

  Chen, Jing Xu ^a   Su, Yun Ai ^a   Bian, Qing Tao ^a   Wei, Li He ^a   Zhang, Rong Zhen ^a   Liu, Yan Hong ^a   Correll, Christoph ^b   Soares, Jair C ^c   Yang, Fu De ^a   Wang, Shao Li ^a   Zhang, Xiang Yang ^a,c  

^a PEKING UNIVERSITY   (China)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

^c University of Texas Harris County Psychiatric Center   (United States)

Author keywords

Aripiprazole; Dose effect; Hyperprolactinemia; Intervention; Placebo controlled trial; Prolactin; Risperidone

Indexed keywords

ARIPIPRAZOLE; LORAZEPAM; PLACEBO; PROLACTIN; PROPRANOLOL; RISPERIDONE; TRIHEXYPHENIDYL; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BARNES AKATHISIA SCALE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; HYPERPROLACTINEMIA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL PATIENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; SIDE EFFECT ASSESSMENT; SIMPSON-ANGUS SCALE; SYMPTOM; TACHYCARDIA; UKU SIDE EFFECTS RATING SCALE; XEROSTOMIA; ADOLESCENT; BLOOD; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; ARIPIPRAZOLE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERPROLACTINEMIA; MALE; MIDDLE AGED; PROLACTIN; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84937551503     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2015.04.011     Document Type: Article

References (53)

1. Ajmal A., Joffe H., Nachtigall L.B. Psychotropic-induced hyperprolactinemia: a clinical review. Psychosomatics 2014, 55:29-36.
2. Association AP Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Association, Washington, DC. fourth ed.
3. Barnes T.R. A rating scale for drug-induced akathisia. Br. J. Psychiatry 1989, 154:672-676.
4. Basterreche N., Zumarraga M., Arrue A., Olivas O., Davila W. Aripiprazole reverses paliperidone-induced hyperprolactinemia. Actas Esp. Psiquiatr. 2012, 40:290-292.
5. Belgamwar R.B., El-Sayeh H.G. Aripiprazole versus placebo for schizophrenia. Cochrane Database Syst. Rev. 2011, CD006622.
6. Branch NPR The clinical global impressions scale. ECDEU Assessment Manual for Psychopharmacology, Revised 1976, 218-222. US Department of Health, Education and Welfare, Rockville, MD. W. Guy (Ed.).
7. Bushe C., Shaw M., Peveler R.C. A review of the association between antipsychotic use and hyperprolactinaemia. J. Psychopharmacol. 2008, 22:46-55.
8. Byerly M.J., Marcus R.N., Tran Q.V., Eudicone J.M., Whitehead R., Baker R.A. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. Schizophr. Res. 2009, 107:218-222.
9. Chen C.K., Huang Y.S., Ree S.C., Hsiao C.C. Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34:1495-1499.
10. Chen J.X., Su Y.A., Wang S.L., Bian Q.T., Liu Y.H., Wang N., Yang F.D., Haile C., Kosten T.R., Zhang X.Y. Aripiprazole treatment of risperidone-induced hyperprolactinemia. J. Clin. Psychiatry 2009, 70:1058-1059.
11. Correll C.U., Shaikh L., Gallego J.A., Nachbar J., Olshanskiy V., Kishimoto T., Kane J.M. Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behavior. Schizophr. Res. 2011, 131:58-62.
12. Findling R.L., Robb A., Nyilas M., Forbes R.A., Jin N., Ivanova S., Marcus R., McQuade R.D., Iwamoto T., Carson W.H. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am. J. Psychiatry 2008, 165:1432-1441.
13. Fleischhacker W.W., Heikkinen M.E., Olie J.P., Landsberg W., Dewaele P., McQuade R.D., Loze J.Y., Hennicken D., Kerselaers W. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int. J. Neuropsychopharmacol. 2010, 13:1115-1125.
14. Fraguas D., Correll C.U., Merchan-Naranjo J., Rapado-Castro M., Parellada M., Moreno C., Arango C. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur. Neuropsychopharmacol. 2011, 21:621-645.
15. Gallego J.A., Bonetti J., Zhang J., Kane J.M., Correll C.U. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970 to 2009. Schizophr. Res. 2012, 138:18-28.
16. Gallego J.A., Nielsen J., De Hert M., Kane J.M., Correll C.U. Safety and tolerability of antipsychotic polypharmacy. Expert Opin. Drug Saf. 2012, 11:527-542.
17. Grunder G., Carlsson A., Wong D.F. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch. Gen. Psychiatry 2003, 60:974-977.
18. Haddad P.M., Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004, 64:2291-2314.
19. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988, 75:800-802.
20. Inder W.J., Castle D. Antipsychotic-induced hyperprolactinaemia. Aust. N.Z. J. Psychiatry 2011, 45:830-837.
21. Inoue T., Domae M., Yamada K., Furukawa T. Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. J. Pharmacol. Exp. Ther. 1996, 277:137-143.
22. Jeong H.G., Lee M.S., Lee H.Y., Ko Y.H., Han C., Joe S.H. Changes in sexual function and gonadal axis hormones after switching to aripiprazole in male schizophrenia patients: a prospective pilot study. Int. Clin. Psychopharmacol. 2012, 27:177-183.
23. Kane J.M., Barnes T.R., Correll C.U., Sachs G., Buckley P., Eudicone J., McQuade R., Tran Q.V., Pikalov A., Assuncao-Talbott S. Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials. J. Psychopharmacol. 2010, 24:1019-1029.
24. Kane J.M., Meltzer H.Y., Carson W.H., McQuade R.D., Marcus R.N., Sanchez R. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J. Clin. Psychiatry 2007, 68:213-223.
25. Kane J.M., Correll C.U., Goff D.C., Kirkpatrick B., Marder S.R., Vester-Blokland E., Sun W., Carson W.H., Pikalov A., Assuncao-Talbott S. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J. Clin. Psychiatry 2009, 70:1348-1357.
26. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
27. Kegeles L.S., Slifstein M., Frankle W.G., Xu X., Hackett E., Bae S.A., Gonzales R., Kim J.H., Alvarez B., Gil R., Laruelle M., Abi-Dargham A. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F] fallypride. Neuropsychopharmacology 2008, 33:3111-3125.
28. Kelly D.L., Wehring H.J., Earl A.K., Sullivan K.M., Dickerson F.B., Feldman S., McMahon R.P., Buchanan R.W., Warfel D., Keller W.R., Fischer B.A., Shim J.C. Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic Elevated prolactin). BMC Psychiatry 2013, 13:214.
29. Kessler R.M. Aripiprazole: what is the role of dopamine D(2) receptor partial agonism?. Am. J. Psychiatry 2007, 164:1310-1312.
30. Kim E., Howes O.D., Kim B.H., Jeong J.M., Lee J.S., Jang I.J., Shin S.G., Turkheimer F.E., Kapur S., Kwon J.S. Predicting brain occupancy from plasma levels using PET: superiority of combining pharmacokinetics with pharmacodynamics while modeling the relationship. J. Cereb. Blood Flow Metab. 2012, 32:759-768.
31. Kishimoto T., De Hert M., Carlson H.E., Manu P., Correll C.U. Osteoporosis and fracture risk in people with schizophrenia. Curr. Opin. Psychiatry 2012, 25:415-429.
32. Kuloglu M., Ekinci O., Albayrak Y., Caykoylu A. Benefits of switching women schizophrenic patients to aripiprazole: a case study and brief review of the literature. Arch. Womens Ment. Health 2010, 13:443-447.
33. La Torre A., Conca A., Duffy D., Giupponi G., Pompili M., Grozinger M. Sexual dysfunction related to psychotropic drugs: a critical review, Part II: Antipsychotics. Pharmacopsychiatry 2013, 46:201-208.
34. Leucht S., Cipriani A., Spineli L., Mavridis D., Orey D., Richter F., Samara M., Barbui C., Engel R.R., Geddes J.R., Kissling W., Stapf M.P., Lassig B., Salanti G., Davis J.M. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013, 382:951-962.
35. Lingjaerde O., Ahlfors U.G., Bech P., Dencker S.J., Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr. Scand. Suppl. 1987, 334:1-100.
36. Li X., Tang Y., Wang C. Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials. PLoS ONE 2013, 8:e70179.
37. Madhusoodanan S., Parida S., Jimenez C. Hyperprolactinemia associated with psychotropics-a review. Hum. Psychopharmacol. 2010, 25:281-297.
38. Montgomery J., Winterbottom E., Jessani M., Kohegyi E., Fulmer J., Seamonds B., Josiassen R.C. Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment. J. Clin. Psychiatry 2004, 65:1491-1498.
39. Newcomer J.W., Weiden P.J., Buchanan R.W. Switching antipsychotic medications to reduce adverse event burden in schizophrenia: establishing evidence-based practice. J. Clin. Psychiatry 2013, 74:1108-1120.
40. Potkin S.G., Saha A.R., Kujawa M.J., Carson W.H., Ali M., Stock E., Stringfellow J., Ingenito G., Marder S.R. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry 2003, 60:681-690.
41. Rainka M.M., Capote H.A., Ross C.A., Gengo F.M. Attenuation of risperidone-induced hyperprolactinemia with the addition of aripiprazole. J. Clin. Pharm. Ther. 2009, 34:595-598.
42. Rocha F.L., Hara C., Ramos M.G. Using aripiprazole to attenuate paliperidone-induced hyperprolactinemia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34:1153-1154.
43. Saitis M., Papazisis G., Katsigiannopoulos K., Kouvelas D. Aripiprazole resolves amisulpride and ziprasidone-induced hyperprolactinemia. Psychiatry Clin. Neurosci. 2008, 62:624.
44. Shim J.C., Shin J.G., Kelly D.L., Jung D.U., Seo Y.S., Liu K.H., Shon J.H., Conley R.R. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo controlled trial. Am. J. Psychiatry 2007, 164:1404-1410.
45. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. Suppl. 1970, 212:11-19.
46. Sparshatt A., Taylor D., Patel M.X., Kapur S. A systematic review of aripiprazole-dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring. J. Clin. Psychiatry 2010, 71:1447-1456.
47. Suzuki Y., Sugai T., Fukui N., Watanabe J., Ono S., Tsuneyama N., Saito M., Someya T. Differences in plasma prolactin levels in patients with schizophrenia treated on monotherapy with five second-generation antipsychotics. Schizophr. Res. 2013, 145:116-119.
48. van Kooten M., Arends J., Cohen D. Preliminary report: a naturalistic study of the effect of aripiprazole addition on risperidone-related hyperprolactinemia in patients treated with risperidone long acting injection. J. Clin. Psychopharmacol. 2011, 31:126-128.
49. Wang L.J., Ree S.C., Huang Y.S., Hsiao C.C., Chen C.K. Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 40:260-266.
50. Yasui-Furukori N., Furukori H., Sugawara N., Fujii A., Kaneko S. Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia. J. Clin. Psychopharmacol. 2010, 30:596-599.
51. Yokoi F., Grunder G., Biziere K., Stephane M., Dogan A.S., Dannals R.F., Ravert H., Suri A., Bramer S., Wong D.F. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 2002, 27:248-259.
52. Yoo H.K., Joung Y.S., Lee J.S., Song D.H., Lee Y.S., Kim J.W., Kim B.N., Cho S.C. A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette's disorder. J. Clin. Psychiatry 2013, 74:e772-e780.
53. Ziadi Trives M., Bonete Llacer J.M., Garcia Escudero M.A., Martinez Pastor C.J. Effect of the addition of aripiprazole on hyperprolactinemia associated with risperidone long-acting injection. J. Clin. Psychopharmacol. 2013, 33:538-541.